Welcome to our dedicated page for Casi Pharmaceuticals SEC filings (Ticker: CASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how CAR-T hopeful CNCT-19 or anti-CD38 antibody CID-103 might reshape future revenue is difficult when CASI Pharmaceuticals disclosures stretch across dozens of forms. Even the most diligent reader of the CASI Pharmaceuticals annual report 10-K simplified can miss key details on EVOMELA® sales in China, while keeping tabs on CASI Pharmaceuticals insider trading Form 4 transactions adds another layer of complexity.
Stock Titan eliminates that friction. Our AI reviews every CASI Pharmaceuticals quarterly earnings report 10-Q filing, each CASI Pharmaceuticals 8-K material events explained, and the full CASI Pharmaceuticals proxy statement executive compensation the moment EDGAR publishes them. The result: "understanding CASI Pharmaceuticals SEC documents with AI" shifts from aspiration to reality. Need alerts on CASI Pharmaceuticals Form 4 insider transactions real-time? We surface them in seconds, highlighting buys or sells that often precede critical trial readouts.
Put the insights to work:
- Run CASI Pharmaceuticals earnings report filing analysis to see R&D spend, cash runway, and segment revenue without combing through tables.
- Track CASI Pharmaceuticals executive stock transactions Form 4 against upcoming regulatory milestones.
- Get "CASI Pharmaceuticals SEC filings explained simply" summaries for risk factors, pipeline updates, and licensing agreements.
From real-time updates to plain-English explanations, Stock Titan delivers a complete view of CASI’s regulatory narrative—saving hours and empowering faster, better-informed decisions.
Foresite Capital Fund VI, L.P., together with its general partner Foresite Capital Management VI, LLC and James Tananbaum, report beneficial ownership of 787,121 ordinary shares of CASI Pharmaceuticals, representing 5.1% of the outstanding class based on 15,492,581 shares outstanding. All 787,121 shares are reported as directly owned by Foresite Capital Fund VI, with the reporting persons asserting sole voting and sole dispositive power over those shares and no shared power. The filing includes a certification that the securities were not acquired to change or influence control of the issuer and indicates the holdings are held as passive investments. The filers executed a joint filing agreement.
FAQ
What is the current stock price of Casi Pharmaceuticals (CASI)?
What is the market cap of Casi Pharmaceuticals (CASI)?
